Therapeutic high affinity T cell receptor targeting a KRAS G12D cancer neoantigen.

MLA

Poole, Andrew, et al. “Therapeutic High Affinity T Cell Receptor Targeting a KRAS G12D Cancer Neoantigen.” Nature Communications, vol. 13, no. 1, Sept. 2022, p. 5333. EBSCOhost, https://doi.org/10.1038/s41467-022-32811-1.

APA

Poole, A., Karuppiah, V., Hartt, A., Haidar, J. N., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C., Dias, J., Harper, S., Barnbrook, K., Hock, M., Coles, C., Yang, W., Aleksic, M., Lin, A. B., Robinson, R., Dukes, J. D., Liddy, N., … Chillakuri, C. (2022). Therapeutic high affinity T cell receptor targeting a KRAS G12D cancer neoantigen. Nature Communications, 13(1), 5333. https://doi.org/10.1038/s41467-022-32811-1

Chicago

Poole, Andrew, Vijaykumar Karuppiah, Annabelle Hartt, Jaafar N Haidar, Sylvie Moureau, Tomasz Dobrzycki, Conor Hayes, et al. 2022. “Therapeutic High Affinity T Cell Receptor Targeting a KRAS G12D Cancer Neoantigen.” Nature Communications 13 (1): 5333. doi:10.1038/s41467-022-32811-1.